23 results on '"Chew-Harris, J."'
Search Results
2. Novel Preservation of Cardiac Mitochondrial Integrity by suPAR Following Anoxia-Reoxygenation Injury
3. Convalescent GDF-15 and Long-Term Outcomes After Acute Coronary Syndrome
4. Beware the dog that didnʼt bark: a tale of creatinine in acute kidney injury
5. Removal of body surface area normalisation improves raw-measured glomerular filtration rate estimation by the Chronic Kidney Disease Epidemiology Collaboration equation and drug dosing in the obese
6. Lean mass modulates glomerular filtration rate in males of normal and extreme body composition
7. Protein Glycosylation Influences Soluble Urokinase Plasminogen Activator Receptor (suPAR) Measurements
8. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Promotes Cardioprotective Intracellular Signalling in Myocardial Ischaemia
9. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 2-Year Cardiovascular Events in Patients After Acute Chest Pain
10. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts Mortality in Patients With Acute Chest Pain
11. Erythroferrone can Diagnose Acute Decompensated Heart Failure in Patients Presenting With Breathlessness
12. Prognostic Performance of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Predicting Mortality in Asian and Western Patients With Acute Breathlessness
13. Prognostic performance of soluble urokinase plasminogen activator receptor for 1-year mortality in Asian and Western patients with acute breathlessness
14. Soluble urokinase plasminogen activator receptor (suPAR) can predict long-term mortality in patients with acute chest pain
15. Soluble urokinase plasminogen activator receptor (suPAR) predicts 2-year cardiovascular events in patients after acute chest pain
16. P2616Soluble urokinase plasminogen activator receptor (suPAR) predicts 1 year mortality in patients with acute breathlessness
17. P3408The signal peptide of CNP is a novel predictor of MI, MACE and bleeding risk in chest pain patients
18. Prognostic performance of soluble urokinase plasminogen activator receptor for heart failure or mortality in Western and Asian patients with acute breathlessness.
19. Convalescent Growth Differentiation Factor-15 and Long-Term Outcomes after an Acute Coronary Syndrome.
20. Circulating erythroferrone has diagnostic utility for acute decompensated heart failure in patients presenting with acute or worsening dyspnea.
21. suPAR in cardiovascular disease.
22. Analytical and biological assessment of circulating human erythroferrone.
23. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.